Want to join the conversation?
$LLY said that U.S. FDA approved Portrazza, a necitumumab injection for IV use, 800 mg/50 mL in combination with gemcitabine & cisplatin, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC). The approval was based on the results of a Phase III trial named SQUIRE.
$PYPL jumps 6% in after hours on strong results. I am bullish on this stock.
$TSCO stock remained active in the after hours trading and rose more than 2% after the retailer posted better than expected 1Q17 results.
Instagram has reached 700 million monthly active users. Looks like it will hit 1 billion soon. That would make it $FB’s fourth billion-user platform.